Xencor
465 North Halstead Street, Suite 200
Pasadena
California
91107
United States
Tel: 626-305-5900
Website: http://www.xencor.com/
332 articles about Xencor
-
Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies
10/4/2021
Xencor, Inc. today announced an exclusive collaboration and worldwide license agreement with Janssen Biotech, Inc. to develop and commercialize plamotamab and novel XmAb® B-cell targeting bispecific antibodies that are designed to conditionally activate T cells through the CD28 co-stimulatory receptor.
-
The deal has a value of over one billion dollars, with highlights for Xencor including receiving a $100 million upfront payment, a $25 million equity investment, eligibility for plamotamab royalties and potential milestone payments worth up to $1.18 billion.
-
Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting
10/1/2021
Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb ® 717) and Four Research Programs at the SITC Annual Meeting
-
Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference
9/20/2021
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Virtual Global Healthcare Conference
-
Xencor Reports Second Quarter 2021 Financial Results
8/4/2021
Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, reported financial results for the second quarter ended June 30, 2021 and provided a review of recent business and portfolio highlights.
-
Xencor to Present at Upcoming Investor Conferences - Aug 02, 2021
8/2/2021
Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, announced that company management will participate in the following upcoming investor events and conferences:
-
Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021
7/28/2021
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release second quarter 2021 financial results after the market closes on Wednesday, August 4, 2021.
-
Xencor to Present at the Jefferies Virtual Healthcare Conference
5/27/2021
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present a corporate overview at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 1:00 p.m. ET / 10:00 a.m. PT.
-
Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend™ XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
5/25/2021
Xencor, Inc. announced it has entered into a technology license agreement with Bristol-Myers Squibb Company under which Bristol Myers Squibb will have non-exclusive access to Xencor’s Xtend™ Fc technology to extend the half-life of a novel antibody combination therapy that is intended to neutralize the SARS-CoV-2 virus for treatment or prevention of COVID-19.
-
Xencor to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference
5/12/2021
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Virtual Conference
-
Xencor Reports First Quarter 2021 Financial Results
5/5/2021
Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, reported financial results for the first quarter ended March 31, 2021 and provided a review of recent business and clinical highlights.
-
Xencor to Host First Quarter 2021 Financial Results Webcast and Conference Call on May 5, 2021
4/28/2021
Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, announced that it will release first quarter 2021 financial results after the market closes on Wednesday, May 5, 2021.
-
Xencor Doses First Subject in Phase 1 Study of XmAb®564, an Engineered IL-2 Cytokine in Development for Autoimmune Diseases
4/28/2021
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical study of XmAb564
-
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021
4/10/2021
Xencor, Inc. announced the presentation of new data from multiple preclinical XmAb® bispecific antibody programs and its preclinical IL-12-Fc cytokine program at the American Association for Cancer Research Annual Meeting, being held virtually April 10-15, 2021.
-
Xencor to Present Preclinical Data from Four Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2021
3/11/2021
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on three XmAb® bispecific antibody programs and the IL-12-Fc cytokine program at the American Association for Cancer Research (AACR) Annual Meeting,
-
Xencor to Present at the Barclays Global Healthcare Conference
3/3/2021
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will participate in a virtual fireside chat at the Barclays Global Healthcare Conference
-
Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb® Therapeutics
2/25/2021
Collaboration joins together Xencor's modular XmAb engineered protein platforms with UCLA's expertise in biology to rapidly create and advance potential new medicines
-
Xencor to Host Fourth Quarter and Full Year 2020 Financial Results Webcast and Conference Call on February 23, 2021
2/16/2021
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release fourth quarter and full year 2020 financial results after the market closes on Tuesday, February 23, 2021.
-
Xencor to Present at Upcoming Investor Conferences - Feb 04, 2021
2/4/2021
Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, announced that company management will participate at two upcoming investor conferences:
-
miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease
12/17/2020
Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology miRagen expects to file an Investigational New Drug (IND) application for VRDN-002, including half-life extension, by the end of 2021